Repligen Reports Strong Q2 Results, Raises Full-Year Revenue & Adjusted EPS Guidance
RGEN sits 32% above its 52-week low of $100.99.
Summary
Repligen announced strong Q2 2026 financial results with 13% organic revenue growth and a 55% increase in adjusted operating income, leading to an upward revision of its full-year guidance.
Key Events · Earnings and Guidance · RGEN
-
Q2 Revenue Growth
Reported $204 million in Q2 revenue, a 12% year-over-year increase (13% organic).
-
Adjusted Profitability Surges
Adjusted operating income increased 55% to $34 million, and adjusted EPS rose to $0.54 from $0.37 year-over-year.
-
Full-Year Guidance Raised
Increased full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09.
-
Strong Cash Position
Ended Q2 with $810 million in cash, cash equivalents, and marketable securities.
Analysis · RGEN · Life Sciences
Repligen delivered robust second-quarter financial results, exceeding expectations with strong organic revenue growth and a significant increase in adjusted operating income and EPS. The company also raised its full-year 2026 guidance for both organic revenue growth and adjusted earnings per share, indicating increased confidence in its business outlook. This positive performance comes shortly after the announcement of a major acquisition, suggesting the company is executing well on both organic growth and strategic expansion.
At the time of this filing, RGEN was trading at $133.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $100.99 to $175.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.